Advancing Pharmacotherapy is Outpacing Support in Obesity Care

Current State of Affairs

As clinicians, many of us are witnessing a shift that feels both hopeful and overwhelming. GLP-1 medications have fundamentally changed what’s possible in obesity and cardiometabolic care. Large clinical trials of agents like semaglutide and tirzepatide demonstrate average weight loss of 15-20%, along with meaningful improvements in glycemia management and cardiometabolic risk factors. ¹ ² For patients who’ve struggled for years, these therapies can be life-changing.

However, prescribing the medication is just the first step. The reality is patients need ongoing support to sustain progress, and ultimately maintenance, long-term. Despite these needs, the current gap in healthcare infrastructure is frustrating (for patients and clinicians alike) and hinders continuous obesity care. Appointments are brief and follow-up intervals are long while messages pile up in patient portals waiting to be answered by clinicians. Many patients are motivated but unsure or unaware of how to adjust behaviors in ways that align with their medication. Others face insurance denials or abrupt discontinuation that leave them feeling abandoned by the system. Clinicians want to help, but limited time and staffing, as well as reimbursement constraints make it nearly impossible to provide the level of ongoing guidance these therapies demand.

Redefining the Prevalence of Obesity

“...Historical [obesity] prevalence rates likely underestimate the true scale and clinical burden of unmet needs and underscore why current care models are stretched beyond capacity”. ⁴

The scope of this challenge is larger than many realize. Using traditional BMI-based definitions, ~40% of U.S. adults are classified as having obesity. ³ When broader, complication-based criteria such as the American Association of Clinical Endocrinology’s adiposity-based chronic disease model are applied, obesity is understood as a chronic, progressive disease defined by adipose distribution and dysfunction as well as related complications rather than BMI alone. This clinically relevant criteria highlights how historical prevalence rates likely underestimate the true scale and clinical burden of unmet needs and underscore why current care models are stretched beyond capacity. ⁴

Weight Bias & Stigma

What often goes unspoken is how weight bias and stigma actively worsen health outcomes for people living with obesity. Decades of research show that weight stigma is associated with delayed care-seeking, reduced trust in clinicians, increased stress, disordered eating, lower physical activity, and higher rates of depression and anxiety. ⁵ ⁶ Patients who’ve experienced weight-based bias in healthcare settings are less likely to attend preventive visits and more likely to disengage from treatment altogether. Ultimately, stigma is not a side issue; it’s a direct barrier to effective care.

“...Stigma is not a side issue; it’s a direct barrier to effective care”.

Despite this, there are no comprehensive federal protections against weight-based discrimination in healthcare, employment, or education. Only a handful of jurisdictions in the United States include weight as a protected characteristic under anti-discrimination laws. As a result, patients with obesity routinely encounter prejudice that would be unacceptable if directed toward other chronic conditions. This lack of policy protection reinforces outdated narratives that frame obesity as a personal failing rather than a chronic, relapsing disease influenced by biology, environment, and social determinants of health.

Lack of Coverage for Behavioral Support

Insurance policy further compounds these inequities. Medicare covers intensive behavioral therapy for obesity only when provided by PCPs in a primary care setting; a restriction that effectively excludes many registered dietitians and behavioral health clinicians from direct reimbursement. ⁷ These limitations disproportionately affect patients with fewer financial resources, widening health disparities and increasing the long-term burden of obesity-related complications such as type 2 diabetes and cardiovascular disease.

How Alnu Health Improves Obesity Care Infrastructure Within the Healthcare Ecosystem

Alnu is designed to support patients prescribed GLP-1 medications between appointments, since most challenges arise outside the clinic. Our platform provides evidence-based guidance on nutrition, physical activity, behavioral strategies, and side effect management in a way that’s consistent, nonjudgmental, and longitudinal. Research shows that frequent contact, self-monitoring, and supportive feedback are associated with improved adherence and better outcomes, particularly when care is delivered without stigma. ⁸

“Our platform provides evidence-based guidance [...] in a way that’s consistent, nonjudgmental, and longitudinal”.

From a clinician perspective, Alnu extends capacity without adding to workload. Patients track medication use, symptoms, and behaviors through the platform, and those data are synthesized into actionable insights. This allows clinicians to make more informed titration decisions, identify problems earlier, and personalize care more effectively. Digital monitoring and guided self-management have been shown to improve adherence and outcomes across chronic diseases, including obesity. ⁹

Another critical but often overlooked component of obesity care is community. Many patients turn to social media for connection, where information is frequently inaccurate or harmful. Alnu offers moderated peer-support spaces grounded in medical evidence and respect, creating a trusted environment where patients can share experiences without shame. Peer support has been shown to improve engagement, self-efficacy, and long-term adherence in chronic disease management. ¹⁰

What the Future Holds

Looking ahead, the future of obesity and cardiometabolic care will depend on hybrid models that combine clinician expertise with scalable digital support. Clinicians remain essential for complex, shared decision-making with their patients while digital tools like Alnu provide the day-to-day structure, education, and reassurance patients need to succeed. This approach supports patients while also reducing clinician burnout and healthcare system strain.

“Patients do not fail obesity treatment; systems do”.

At its core, Alnu Health is built on a simple clinical truth: Patients do not fail obesity treatment; systems do. When we remove stigma, provide consistent support, and align care models with the realities of chronic disease, outcomes improve. By supporting patients and clinicians together, Alnu aims to close one of the most critical gaps in modern healthcare and help redefine obesity care in a way that is evidence-based, equitable, and compassionate.

Key Takeaways

• Obesity is a chronic, relapsing disease affecting the majority of U.S. adults when diagnosed using modern, complication-based criteria. Advances in GLP-1 medications have significantly improved clinical outcomes, but medication alone is insufficient without ongoing support.
• Patient needs between healthcare visits far exceed what clinicians and hospital systems can realistically provide through traditional care models alone.
• Weight bias and stigma remain pervasive in healthcare and society, directly contributing to delayed care and poorer health outcomes.
• Alnu Health is a scalable digital health solution that extends clinician reach, supports patients between visits, and improves adherence without increasing clinician burden.
• Closing the gap in obesity care will require coordinated clinical innovation, social support, and policy reform.